The PROMISE II Trial, Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia (PROMISE)
Diseases of the Cardiovascular System
What is the purpose of this trial?
The LimFlow System is intended for endovascular, minimally invasive procedures in patients who have a clinical diagnosis of chronic limb-threatening ischemia and who have been determined to have no surgical or endovascular treatment option (i.e., "no option").
- Ages18 years - 95 years
- Trial withLimFlow SA
- Start Date09/02/2020
- End Date07/29/2021
- Last Updated10/07/2020
- Study HIC#2000027620